Researchers find experimental drug can help fight debilitating side effect of ovarian cancer Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. A drug that inhibits a receptor called the ’Colony Stimulating Factor 1 Receptor’ reduces ascites with minimal side effects.
Cancer cells poised for growth when opportunity knocks Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer.
Small RNA has big impact on prostate cancer microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer, new research concludes. This small RNA fragment hit multiple targets, reducing androgen receptor signaling and reviving the potency of enzalutamide, a treatment for advanced prostate cancer. In addition, miR-124 impeded EZH2 and Src, proteins that contribute to treatment resistance.
Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
No comments:
Post a Comment